4.3 Article

Andrographolide ameliorates OVA-induced lung injury in mice by suppressing ROS-mediated NF-κB signaling and NLRP3 inflammasome activation

Journal

ONCOTARGET
Volume 7, Issue 49, Pages 80262-80274

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.12918

Keywords

andrographolide; asthma; NF-kappa B; NLRP3; ROS; Immunology and Microbiology Section; Immune response; Immunity

Funding

  1. Natural Science Foundation of China [91429308, 81402938, 81422050, 81673437]
  2. Natural Science Foundation of Jiangsu Province [BK2014575]

Ask authors/readers for more resources

In this study, we attempted to explore the effect and possible mechanism of Andrographolide on OVA-induced asthma. OVA challenge induced significant airway inflammatory cell recruitment and lung histological alterations, which were ameliorated by Andrographolide. The protein levels of cytokines in bron-choalveolar fluid (BALF) and serum were reduced by Andrographolide administration as well as the mRNA levels in lung tissue. Mechanically, Andrographolide markedly hampered the activation of nuclear factor-kappa B (NF-kappa B) and NLRP3 inflammasome both in vivo and vitro thus decreased levels of TNF-alpha and IL-1 beta. Finally, we confirmed that ROS scavenging was responsible for Andrographolide's inactivation of NF-kappa B and NLRP3 inflammasome signaling. Our study here revealed the effect and possible mechanism of Andrographolide on asthma, which may represent a new therapeutic approach for treating this disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available